原发性腹膜后肉瘤根治性切除术后并发症:跨大西洋RPS工作组报告
该回顾性多中心研究纳入1007例原发性腹膜后肉瘤根治性切除患者,发现Clavien-Dindo≥3级严重并发症发生率为16.4%,30天死亡率为1.8%。年龄、输血需求和切除器官评分是严重并发症的显著预测因素,胰十二指肠切除、大血管切除和脾切除/胰腺切除风险较高。术后并发症对总生存、局部复发或远处转移无影响。
要点
- 在专科肉瘤中心行根治性切除是安全的,严重并发症率16.4%,30天死亡率1.8%。
- 年龄、输血需求和切除器官评分是严重并发症的显著预测因素。
- 胰十二指肠切除、大血管切除和脾切除/胰腺切除风险较高(OR>1.5)。
核心结论
- 在专科肉瘤中心行根治性切除治疗腹膜后肉瘤是安全的。
- 高风险切除应个体化权衡预期疾病生物学行为。
- 手术并发症与长期肿瘤学结局无关联。
研究设计与样本
- 采用加权器官评分反映手术复杂度,行单因素和多因素logistic回归分析。
主要发现
- 严重术后不良事件(Clavien-Dindo≥3级)发生于165例(16.4%),18例(1.8%)在30天内死亡。
- 严重不良事件的显著预测因素为年龄(P=0.003)、输血需求(P<0.001)和切除器官评分(P=0.042)。
- 涉及胰十二指肠切除、大血管切除和脾切除/胰腺切除的手术风险较高(比值比>1.5)。
- 术后不良事件对总生存、局部复发或远处转移无影响。
关键数值与推荐
- 严重术后不良事件定义为Clavien-Dindo≥3级。
- 高风险手术包括胰十二指肠切除、大血管切除和脾切除/胰腺切除(比值比>1.5)。
临床怎么用
- 在专科肉瘤中心开展根治性切除,严重并发症率和30天死亡率可接受。
- 对涉及胰十二指肠切除、大血管切除或脾切除/胰腺切除的高风险患者应个体化评估。
- 术后并发症不直接影响长期肿瘤学结局,但需关注高风险患者围术期管理。
局限性
- 回顾性研究设计。
- 来自专科肉瘤中心经验,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the safety of radical resection for retroperitoneal sarcoma (RPS). BACKGROUND: The surgical management of RPS frequently involves complex multivisceral resection. Improved oncologic outcomes have been demonstrated with this approach compared to marginal excision, but the safety of radical resection has not been shown in a large study population. METHODS: The Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG) is an international collaborative of sarcoma centers. A combined experience of 1007 consecutive resections for primary RPS from January 2002 to December 2011 was studied retrospectively with respect to adverse events. A weighted organ score was devised to account for differences in surgical complexity. Univariate and multivariate logistic regression analyses were performed to investigate associations between adverse events and number and patterns of organs resected. Associations between adverse events and overall survival, local recurrence, and distant metastases were investigated. RESULTS: Severe postoperative adverse events (Clavien-Dindo ≥3) occurred in 165 patients (16.4%) and 18 patients (1.8%) died within 30 days. Significant predictors of severe adverse events were age (P = 0.003), transfusion requirements (P < 0.001), and resected organ score (P = 0.042). Resections involving pancreaticoduodenectomy, major vascular resection, and splenectomy/pancreatectomy were found to entail higher operative risk (odds ratio >1.5). There was no impact of postoperative adverse events on overall survival, local recurrence, or distant metastases. CONCLUSIONS: A radical surgical approach to RPS is safe when carried out at a specialist sarcoma center. High-risk resections should be carefully considered on an individual basis and weighed against anticipated disease biology. There appears to be no association between surgical morbidity and long-term oncologic outcomes.
引用
- MacNeill AJ, Gronchi A, Miceli R, et al. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group. Ann Surg. 2018. PMID: 28394870. doi:10.1097/SLA.0000000000002250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。